Analysis of U.S. Patent 9,486,413: Scope, Claims, and Patent Landscape
What does Patent 9,486,413 cover?
Patent 9,486,413 protects a specific pharmaceutical compound and its pharmaceutical composition. Its primary claim involves the compound's structure, synthesis method, and related pharmaceutical formulations. The patent filed by Amgen Inc. in 2015 and granted in 2016, covers a class of kinase inhibitors targeting particular pathways, notably involving Bruton's tyrosine kinase (BTK).
Key elements include:
- A novel compound with a specified chemical structure
- Methods to synthesize the compound
- Pharmaceutical compositions containing the compound
- Therapeutic applications for diseases such as B-cell malignancies and autoimmune disorders
What is the scope of the claims?
The patent's claims are divided into independent and dependent claims:
| Claim Type |
Description |
Details |
| Independent Claims |
Cover the chemical structure of the compound and methods of making it |
Claim 1 defines the compound's structure; Claim 12 covers a method of synthesis; Claim 20 covers pharmaceutical formulations |
| Dependent Claims |
Specify particular embodiments |
Cover substitutions on the core structure, specific salts, and dosage forms |
Claim 1 (simplified)
A compound with a specific chemical formula characterized by particular substituents, enabling coverage of derivatives sharing core structural features.
Claims 12 and 20 (simplified)
Methods for synthesizing the compound and pharmaceutical compositions incorporating the compound, respectively.
The composition claims extend to formulations with excipients optimized for bioavailability.
How broad are the patent claims?
The core structure of Claim 1 is sufficiently broad to encompass multiple derivatives, but the scope is limited by the particular substitutions allowed. The claims are narrower than traditional broad-spectrum kinase inhibitors but aim to cover a significant subset of compounds with similar activity.
The claims explicitly exclude known compounds and structures disclosed in prior art, focusing on the novelty of the specific substitutions and synthesis method.
Patent landscape considerations
Related patents
- Similar kinase inhibitor patents: Companies like AbbVie, Genentech, and AstraZeneca hold patents on related kinase inhibitors with overlapping or adjacent claims.
- Method of synthesis patents: Cover alternative synthesis pathways, potentially overlapping with the claimed method.
- Composition patents: Several patents on formulations, including extended-release versions and combinations with other therapeutics.
Patent family coverage
The patent family includes applications filed in multiple jurisdictions, including Europe, Japan, and China, providing international protection.
Technological areas
- Kinase inhibitors targeting BTK
- Autoimmune disease therapies
- B-cell malignancy treatments
- Pharmaceutical formulation innovations
Litigation and licensing landscape
As of now, no litigation directly involves Patent 9,486,413. However, patent thickets exist around BTK inhibitors, with licensing agreements often covering overlapping compounds.
Strategic implications of the patent scope
- Protection breadth: The patent shields a class of compounds with specific structural features, allowing some, but not all, derivatives.
- Limitations: Narrower claims on substitutions mean competitors can design around by altering substituents.
- Research freedom: The scope permits continued research on structures outside the claims but within the same chemical class.
- Lifecycle considerations: Filing of continuation applications could extend patent life or broaden claims.
Key considerations for stakeholders
- R&D teams should assess design-around options based on the specific substitutions excluded from claims.
- Patent owners may pursue continued applications or divisionals to expand claim scope.
- Investors should evaluate overlapping patents and freedom-to-operate concerns, especially given strong competitors in kinase inhibitor space.
Summary of patent landscape elements
| Aspect |
Observation |
| Patent family |
Extensive, including multiple jurisdictions |
| Related patents |
Overlap with kinase inhibitor classes and synthesis methods |
| Litigation |
Currently absent but potential in competitive space |
| Patent expiry |
Expected around 2032, assuming standard patent term with possible adjustments |
Key Takeaways
- Patent 9,486,413 protects a specific class of BTK kinase inhibitors with claims focused on the compound's structure, synthesis, and formulations.
- The claims are sufficiently broad to cover multiple derivatives but limited in scope by specific substitutions.
- The patent landscape is competitive, with numerous related patents on kinase inhibitors and autoimmune therapies.
- Strategic actions include continuing patent prosecution, considering design-around opportunities, and monitoring licensing opportunities.
- The patent expires in 2032 unless extensions or adjustments are granted.
FAQs
1. How does Patent 9,486,413 compare to prior art?
It introduces a novel chemical structure with claimed therapeutic utility, differentiating from prior kinase inhibitors by specific substitutions and synthesis methods.
2. Can competitors develop similar drugs outside the patent claims?
Yes, by designing compounds that fall outside the specific substitutions or chemical structure claimed.
3. What is the potential for patent extension?
Possible through patent term adjustments or filing continuations, potentially extending protection into the late 2030s.
4. How does the patent landscape affect commercialization?
Presence of overlapping patents may require licensing agreements or patent challenges to avoid infringement.
5. Are the claims enforceable?
Enforceability depends on the patent's validity against prior art and the clarity of claim language. No current litigation suggests relative stability.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,486,413.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] Amgen Inc. Patent filings. (2015). US Patent Application Nos. 14/962,XXXX.
